Suppr超能文献

晚期早产儿生长受限的产前皮质激素治疗。

Antenatal corticosteroids in the late preterm period for growth-restricted pregnancies.

机构信息

Department of Obstetrics and Gynecology, ChristianaCare, Newark, DE.

Department of Obstetrics and Gynecology, ChristianaCare, Newark, DE.

出版信息

Am J Obstet Gynecol MFM. 2020 Aug;2(3):100153. doi: 10.1016/j.ajogmf.2020.100153. Epub 2020 Jun 13.

Abstract

BACKGROUND

Recently, the Antenatal Late Preterm Steroids study reported that antenatal corticosteroids administered in the late preterm period (34.0-36.6 weeks' gestation) reduced the rate of neonatal respiratory complications at birth. The utility of this intervention in women with fetal growth restriction remains unclear.

OBJECTIVE

This study aimed to determine whether administration of antenatal corticosteroids in the late preterm period in pregnancies with growth restriction decreased the need for respiratory support at delivery and other neonatal morbidities.

STUDY DESIGN

This was a single-center retrospective cohort study that included growth-restricted pregnancies delivered in the late preterm period. Growth restriction was defined as either a diagnosis of fetal growth restriction or small for gestational age by birthweight less than 10%. The primary composite outcome consisted of any 1 of the following occurring in a single neonate: requirement of continuous positive airway pressure or high-flow nasal cannula for 2 hours or more, oxygen requirement with fraction of inspired oxygen of ≥30% for 4 hours or more, mechanical ventilation at any time, stillbirth, or neonatal death. The primary outcome was compared between steroid naive pregnancies and pregnancies exposed to betamethasone in the late preterm period. Univariable and multivariable statistical analysis was performed and P<.05 was considered statistically significant.

RESULTS

A total of 247 women with a diagnosis of growth restriction or small for gestational age met all inclusion criteria, 111 of whom did not receive antenatal corticosteroids and 136 received late preterm antenatal corticosteroids. Demographics were similar between the groups, with the exception of those who received betamethasone being more likely to be nulliparous (P=.01) and to receive a diagnosis of preeclampsia (P=.001). The primary outcome did not differ between the 2 groups (16.2% [18/111] vs 12.5% [17/136]; P=.41). Multivariable modeling controlling for parity and preeclampsia indicated that the rate of the primary composite respiratory outcome was similar between the exposure groups (adjusted odds ratio, 0.63; P=.29). Neonatal hypoglycemia (<40 mg/dL) was more common in newborns exposed to steroids (25.2% [28 /111] vs 40.4% [55/136]; P=.012).

CONCLUSION

Administration of antenatal corticosteroids in the late preterm period for pregnancies with growth restriction did not significantly decrease the need for respiratory support in newborns at our institution. The rate of neonatal hypoglycemia increased after exposure to antenatal corticosteroids. This special population may not benefit from late preterm steroids.

摘要

背景

最近,《产前晚期早产儿皮质类固醇研究》报告称,在晚期早产儿(34.0-36.6 孕周)期给予产前皮质类固醇可降低新生儿出生时呼吸并发症的发生率。这种干预措施在胎儿生长受限的女性中的应用效果尚不清楚。

目的

本研究旨在确定在生长受限的妊娠中晚期早产儿期给予产前皮质类固醇是否会降低分娩时呼吸支持的需求和其他新生儿并发症的发生率。

研究设计

这是一项单中心回顾性队列研究,纳入了在晚期早产儿期分娩的生长受限妊娠。生长受限的定义为通过出生体重小于 10%来诊断胎儿生长受限或小于胎龄儿。主要复合结局包括单个新生儿出现以下任何 1 种情况:需要持续气道正压通气或高流量鼻导管通气 2 小时或更长时间,需要吸入氧分数为 30%或更高的氧气 4 小时或更长时间,任何时间需要机械通气,死胎或新生儿死亡。将未接受产前皮质类固醇的妊娠与接受晚期产前皮质类固醇的妊娠进行比较。进行单变量和多变量统计分析,P<.05 被认为具有统计学意义。

结果

共有 247 名患有生长受限或小于胎龄的女性符合所有纳入标准,其中 111 名未接受产前皮质类固醇治疗,136 名接受了晚期产前皮质类固醇治疗。两组的人口统计学特征相似,但接受倍他米松治疗的组更有可能是初产妇(P=.01),并且更有可能被诊断为子痫前期(P=.001)。两组的主要结局无差异(16.2%[18/111] vs 12.5%[17/136];P=.41)。多变量模型控制了产次和子痫前期,表明暴露组的主要复合呼吸结局发生率相似(调整后的优势比,0.63;P=.29)。暴露于类固醇的新生儿低血糖症(<40mg/dL)更为常见(25.2%[28/111] vs 40.4%[55/136];P=.012)。

结论

在我们的机构中,为生长受限的妊娠在晚期早产儿期给予产前皮质类固醇并未显著降低新生儿呼吸支持的需求。暴露于产前皮质类固醇后,新生儿低血糖症的发生率增加。这一特殊人群可能不会从晚期早产儿类固醇中受益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验